The ultimate industry report measuring the progress of business, science and regulation in biotechnology.
"This comprehensive status report on the biotechnology industry, published by BioWorld Today, is a required reference for analysts and investors in biotech, and is a must-have resource for biotech executives in need of factual data that will help show them which way the sector is heading."
With the BioWorld Biotechnology State of the Industry Report 2009, you can tap into 425 pages of proprietary market research that reveals critical data and financial information about trends affecting the biotechnology industry in the U.S. It contains more than 300 up-to-date tables and charts, plus special analysis sections on Wall Street, the FDA, R&D and biotech in Europe.
The new BioWorld Biotechnology State of the Industry Report 2009 gives you every piece of information available to help you analyze developments in the biotechnology industry and stay ahead of the curve. An example of some of the data you receive includes:
Money raised by biotechnology companies last year
Follow-on public offerings
After-market performance (IPOs)
After-market performance for follow-on offerings
IPOs for the past 4 years
Follow-on offerings for the past 4 years
Gross proceeds of biotech public stock offerings for the past 10 years
Venture capital and other financings of private biotechnology firms
Milestones and equity investments from corporate partners
Grants and awards to biotech companies
New agreements between biotech and big-pharma
Modified and terminated agreements between biotech and big-pharma
Ag-bio collaborations
Manufacturing, marketing and distribution agreements
Biotech and university/nonprofit institution collaborations
Mergers and acquisitions: completed, pending and terminated
And much more!
By combining these tables and charts with expert opinions from industry thought-leaders, the BioWorld Biotechnology State of the Industry Report 2009 is the prerequisite for creating dynamic data-driven presentations, preparing business plans and marketing strategies, and deepening your understanding of the biotechnology industry.
People who need this report:
Biotechnology and pharmaceutical executives
Start-ups
Heads of R&D
Analysts
Investors
Law firms serving the sector
Economic development organizations
Technology transfer officers
|
- I. Analysis
- Interesting Times in Biotech: A Blessing or a Curse?
- The Year in Review
- The View from Wall Street
- The View from Washington
- The View from Europe
- The View from the Lab Bench
- II. Financial Data
- Despite Creative Efforts, Biotech Fundraising Halved in 2008
- Money Raised by Biotechnology Companies
- Initial Public Offerings
- Follow-on Offerings
- After-Market Performance (Initial Public Offerings)
- After-Market Performance (Follow-on Offerings)
- Initial Public Offerings: 2005-2008 (Gross Proceeds by Month)
- Follow-on Offerings: 2005-2008 (Gross Proceeds by Month)
- Gross Proceeds of Biotech Public Stock Offerings: by Quarter 1997-2008
- Miscellaneous Financings of Public Biotech Companies
- Venture Capital and Other Financings of Private Biotechnology Firms
- Milestone Payments from Corporate Partners
- Grants, Contracts and Awards to Biotech Companies
- III. Corporate Deals
- Biologics, Patent Expirations May Fuel M&A in 2009
- Biotechnology Mergers and Acquisitions
- Biotech-Big Pharma Collaborations: New Agreements
- Biotech-Big Pharma Collaborations: Modified and Terminated Agreements
- Manufacturing, Marketing and Distribution Agreements with Pharma Companies
- Biotech-Biotech Collaborations
- Biotech-Biotech Modified and Terminated Agreements
- Manufacturing, Marketing and Distribution Agreements Between Biotechnology Companies
- Biotech Miscellaneous Collaborations
- Deals in Agriculture and Animals.
- Biotech-University/Nonprofit Institutions Collaborations
- BioWorld® Biotechnology State of the Industry Report 2009 5
- IV. Biotech Product Development
- Biotechnology Products Approved by the FDA in 2008
- Biotechnology Products on the Market
- FDA Actions on Pending Applications in 2008
- Licensing Applications Filed and Pending at FDA in 2008
- Recommendations by FDA Advisory Panels in 2008
- Overseas Approvals and Actions in 2008
- Orphan Designations Granted in 2008
- V. Report Card For Wall Street
- Methodology Used to Evaluate Underwriter’s Performance
- Top 10 Underwriters: Full Credit to Lead Underwriters; Ranked by Gross Proceeds
- Other Underwriters: Full Credit to Lead Underwriters; Ranked by Gross Proceeds
- Top 10 Underwriters: Full Credit to All Underwriters; Ranked by Gross Proceeds
- Other Underwriters: Full Credit to All Underwriters; Ranked by Gross Proceeds
- Top 10 Underwriters: IPOs (Full Credit to Lead Underwriters; Full Credit to All Underwriters;
- Ranked By Gross Proceeds)
- Top 10 Underwriters: IPOs (Full Credit to Lead Underwriters; Full Credit to All Underwriters;
- Ranked by After-Market Performance)
- Top 10 Underwriters: Full Credit to Lead Underwriters; Ranked by After-Market Performance
- Other Underwriters: Full Credit to Lead Underwriters; Ranked by After-Market Performance
- Top 10 Underwriters: Full Credit to All Underwriters; Ranked by After-Market Performance
- Other Underwriters: Full Credit to All Underwriters; Ranked by After-Market Performance
- VI. Stock Perfomance
- 2008 Stock Report: An Alphabetical Listing of Public Biotech Companies
- 2008 British Stock Report
- 2008 Canadian Stock Report
- BioWorld Stock Indicator vs. Nasdaq Biotech Index
Share this report
Other tasks Related Markets Research & Development Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
